author-photo

Carmen Julia Calfa

University of Miami

17

Papers

145

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Abstract P1-17-03: Impact of a culturally syntonic door-to-door breast cancer early detection intervention

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (21)
Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (19)
OCULAR INVOLVEMENT AS THE INITIAL MANIFESTATION OF T-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

2007 American Journal of Ophthalmology
Show All
- Source
- Cite
- Save
Citations (11)